Biotechnology Archives - Page 2 of 32

BridgeBio Pharma Announces Phase 2 Results From Acoramidis Study

BridgeBio Pharma (NASDQ:BBIO), a commercial-stage biopharmaceutical company developing medicines for patients suffering from genetic diseases and cancers with clear genetic drivers, recently reported updated results from its ongoing Phase 2 study for acoramidis. The study ... [Read]

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

Dec 10

Small biotech Aprea Therapeutics, Inc. APRE announced that the FDA has removed the full clinical hold on a study evaluating its lead product candidate, eprenetapopt (APR-246), in combination with other cancer drugs for treating lymphoid ... [Read]

Why Investors Should Hold on to Universal Health (UHS) Stock

Nov 24

Universal Health Services, Inc. UHS is well poised to grow on the back of accretive acquisitions and robust performance of behavioral health hospitals. Universal Health — with a market cap of $10.2 billion — is ... [Read]

How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%

Nov 18

Shares of Ayala Pharmaceuticals, Inc. (AYLA) have gained 10.1% over the past four weeks to close the last trading session at $10.35, but there could still be a solid upside left in the stock if ... [Read]

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01

Nov 8

Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely non-small cell lung cancer, squamous cell carcinoma ... [Read]

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Oct 21 microsmallcap

SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced ... [Read]

4 Biotechs to Watch Amid Rising Prominence of Gene Therapies

Oct 19

Gene therapy is one of the novel mechanisms of treatment that is attracting several large and small pharma companies. The gene therapies treat a disease by altering or turning off problematic genes and adding genes ... [Read]

ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004

Oct 13

– Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET – First patient in global, 300-patient Phase 2b study of ASLAN004 on track for enrolment in ... [Read]

Social Distancing Creates Pet-Buying Boom that Sends the Industry to New Heights

Jun 1 microsmallcap

As the world shut down and everyone isolated at home, social distancing became the new norm. While it was an important public health measure that saved lives, it also contributed to an increase in anxiety ... [Read]

35 of the Best Ideas Companies to Present at the Summer Solstice – Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021

May 27

RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice – Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be ... [Read]